Antimalarial Drugs Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2025 – 2034
Report ID: GMI4626
Download Free PDF
Authors:
Monali Tayade,
Antimalarial Drugs Market Size
The global antimalarial drugs market generated notable revenues in 2024 and is anticipated to grow at a decent CAGR from 2025 to 2034, propelled by the increase in cases of Malaria, a severe illness caused by Plasmodium parasites delivered by bites from infected mosquitoes. As per WHO, an estimated 263 million cases and 597,000 malaria-related deaths globally took place. The increasing cases of malaria incidence, coupled with the resistance to current antimalarial drugs in a healthcare system that is not adequately developed to deal with endemic disease has led to demand for new therapies.
The growth of the antimalarial drug market has been mainly attributed to the increase in the incidence of malaria treatment considerations, government action, and awareness of adequate treatment and prevention. Subsequently, the opportunity to develop new forms of drug formulations and combination therapies, as well as ongoing research efforts to find new ways to combat drug-resistant vector-borne disease will positively alter the landscape of the antimalarial drug market from a growth perspective.
A major restraining factor in the antimalarial drugs market is the ever-increasing problem of drug resistance. The emergence of resistance against commonly used antimalarial drugs, like artemisinin-based combination therapies (ACTs), is a significant challenge to the effective management of malaria.
To enhance their global presence in the market, companies have been focusing on a number of strategies. First, major pharmaceutical companies have dedicated their research and development (R&D) capabilities to develop new and more effective treatments, especially combating drug-resistant malaria strains. New drug classes, along with innovative drug combinations, are currently being evaluated to ensure higher efficacy with shorter treatment durations.
Antimalarial Drugs Market Trends
There have been notable trends in the market in recent years, many of which stem from changes in drug formulations, an increased emphasis on research into drug-resistant malaria, and the continued global push to eradicate malaria. The introduction of combination therapies including ACTs (Artemisinin-Combination Therapies) as the mainstay of malaria treatment is likely to be top among the trends that have been able to demonstrate their effectiveness for treating multidrug-resistant malaria strains.
In the same vein, there is increasing interest in long-acting injectable formulations intended to minimize treatment regimens while maximizing patient adherence, especially for patients in the developing world when seeking to maintain access to care and treatment such as antimalarial drugs, long-standing injectable formulations that remain in the body and release antimalarial medicine for an extended term could fulfill a gap in the market. The development of next-generation antimalarial drugs that target new mechanisms of parasite resistance could potentially result in more effective treatments for resistant strains, such as Plasmodium falciparum. Additionally, vaccine development is on the rise, and products such as the RTS, and S/AS01 malaria vaccine have shown reduced incidence of viruses and, thus have implications for the existing strategy to work towards eradicating malaria worldwide.
Antimalarial Drugs Market Analysis
The hydroxychloroquine segment held the largest share in 2024 and is projected to hold its leading position through 2034. It was created and approved to treat autoimmune diseases which included rheumatoid arthritis and lupus but has been employed in the treatment of malaria. Hydroxychloroquine is antimalarial, which generates efficacy by killing the Plasmodium malaria parasite that forms the malaria illness and affects humans. Hydroxychloroquine generates efficacy in the treatment of malaria by significantly inhibiting the parasite's use of hemoglobin in the cysts of red blood cells, thus killing the parasite from the malaria illness. Hydroxychloroquine is the leading and most efficacious treatment against uncomplicated malaria by the deadliest malarial parasite Plasmodium falciparum in all cases. Hydroxychloroquine is used in the treatment of malaria, without exception, in combination with one or more antimalarials including chloroquine or azithromycin to develop resistance and increase efficacy.
The treatment segment in the antimalarial drugs market is likely to generate significant revenues until 2034, primarily because the treatment of malaria will fit into only two categories: first-line therapy and second-line therapy. First-line therapy is usually a combination of medications and frequently ACTs (artemisinin-based combination therapies). First-line therapy is considered the best choice for treating malaria due to Plasmodium falciparum. All combinations help address one of the challenges with antimalarial therapy which is resistance and failure to treat over time.
Second-line therapies are used when there is resistance to the first line of therapies or when the patient has no response to the first line of therapy. These stimulants could include depending on the region of the patient, and the strain of malaria, ACT s, chloroquine, quinine, etc. The unified global effort to improve identification and interaction addressing malaria has accomplished an extraordinary amount of work, if you will, regarding the formulation and development of antimalarial drugs. It is encouraging that the multiple antimalarial drugs are used in fixed-dose combinations which promote even more thorough eradication of the parasites facilitating, of course, even less drug resistance. In addition, there are also works in every field of investigation to bring new drugs to market that have faster-acting and accepted side effects such that inordinate periods of treatment do not produce undue patient concern and/or non-compliance.
United States antimalarial drugs market held the largest share in 2024 due to a developed healthcare system focusing on patient care, a developed pharmaceutical industry, and a commitment to researching global public health challenges like malaria. Generally, malaria is rare in the U.S., primarily due to public health measures and travel to areas where malaria is endemic though it is widely recognized that there is a strong market force for antimalarial drugs. Almost all U.S. pharmaceutical companies develop, produce, and distribute antimalarial drugs and treatments worldwide.
The U.S. government has funded international malaria control efforts and partnerships with organizations like the World Health Organization (WHO) and the Global Fund to Fight AIDS, Tuberculosis, and Malaria. U.S. pharmaceutical companies including Gilead Sciences and Merck have been key players in the research and development of new drugs and drug combinations for treating malaria. There are already other drugs with the potential to replace current malaria drug treatments due to humans getting resistance to these drugs or at a minimum provide treatments for human malaria infections that have drug resistance.
Antimalarial Drugs Market Share
Major antimalarial drug industry includes:
To increase their global enterprise in the market companies have been focused on various strategies. First, many companies' R&D (research and development) departments are working to develop new and improved antimalarial therapies, especially focusing on new treatments for drug-resistant malaria. New classes of drugs, and new combinations of drugs, are currently in worldwide clinical trials to create drugs with better efficacy with less therapy duration.
Second, companies have identified partnerships and collaborations with international health organizations and governments to be extremely important in creating and disseminating improved treatments for malaria. Companies (e.g. Novartis, GSK, and Sanofi) have partnered with organizations (e.g. WHO, Global Fund), to distribute antimalarial drugs in malaria-endemic countries to improve their support for global eradication initiatives.
Antimalarial Drugs Industry News
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →